Literature DB >> 17920324

Influence of RANKL inhibition on immune system in the treatment of bone diseases.

Anne Fouque-Aubert1, Roland Chapurlat.   

Abstract

Receptor activator of nuclear factor-kappaB ligand (RANKL) is essential for osteoclast differentiation, activation and survival. Recently, denosumab, a human monoclonal antibody to RANKL, has been tested in the treatment of osteoporosis. But the interactions between RANKL, receptor activator of nuclear factor-kappaB (RANK) and osteoprotegerin (OPG) are also involved in immune regulations in addition to bone metabolism. So, blocking RANKL could interplay with immune cells and have systemic effects. Here, we review biological data regarding potential consequences of RANKL blocking on the immune system.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17920324     DOI： 10.1016/j.jbspin.2007.05.004

Source DB:  PubMed          Journal:  Joint Bone Spine        ISSN： 1297-319X            Impact factor:   4.929


  12 in total

1.  Receptor activator of NF-{kappa}B (RANK) cytoplasmic IVVY535-538 motif plays an essential role in tumor necrosis factor-{alpha} (TNF)-mediated osteoclastogenesis.

Authors:  Joel Jules; Zhenqi Shi; Jianzhong Liu; Duorong Xu; Shunqing Wang; Xu Feng
Journal:  J Biol Chem       Date:  2010-09-24       Impact factor: 5.157

Review 2.  Toll gates to periodontal host modulation and vaccine therapy.

Authors:  George Hajishengallis
Journal:  Periodontol 2000       Date:  2009       Impact factor: 7.589

3.  Development of cell-based high-throughput assays for the identification of inhibitors of receptor activator of nuclear factor-kappa B signaling.

Authors:  Jason W Ashley; Erin M McCoy; Daniel A Clements; Zhenqi Shi; Taosheng Chen; Xu Feng
Journal:  Assay Drug Dev Technol       Date:  2010-11-04       Impact factor: 1.738

Review 4.  RANK ligand: effects of inhibition.

Authors:  Saby George; Andrew Brenner; John Sarantopoulos; Ronald M Bukowski
Journal:  Curr Oncol Rep       Date:  2010-03       Impact factor: 5.075

5.  Association analyses suggest the effects of RANK and RANKL on age at menarche in Chinese women.

Authors:  R Pan; Y-Z Liu; H-W Deng; V Dvornyk
Journal:  Climacteric       Date:  2011-10-24       Impact factor: 3.005

6.  Gene expression variation between African Americans and whites is associated with coronary artery calcification: the multiethnic study of atherosclerosis.

Authors:  Chiang-Ching Huang; Donald M Lloyd-Jones; Xiuqing Guo; Nalini M Rajamannan; Simon Lin; Pan Du; Qiquan Huang; Lifang Hou; Kiang Liu
Journal:  Physiol Genomics       Date:  2011-04-26       Impact factor: 3.107

Review 7.  Current and emerging treatment strategies for breast cancer-induced bone loss.

Authors:  Stephanie L Hines
Journal:  Breast Cancer (Dove Med Press)       Date:  2010-10-28

8.  Disturbance of the OPG/RANK/RANKL pathway and systemic inflammation in COPD patients with emphysema and osteoporosis.

Authors:  Peng Bai; Yongchang Sun; Jianmin Jin; Jia Hou; Ran Li; Qing Zhang; Yang Wang
Journal:  Respir Res       Date:  2011-12-16

9.  Effect of echinalkamide identified from Echinacea purpurea (L.) Moench on the inhibition of osteoclastogenesis and bone resorption.

Authors:  Bo Yoon Chang; Seul Ki Lee; Da Eun Kim; Jin Hye Bae; Thanh Tam Ho; So-Young Park; Mi Kyeong Lee; Sung Yeon Kim
Journal:  Sci Rep       Date:  2020-07-02       Impact factor: 4.379

Review 10.  From the Clinical Problem to the Basic Research-Co-Culture Models of Osteoblasts and Osteoclasts.

Authors:  Sheng Zhu; Sabrina Ehnert; Marc Rouß; Victor Häussling; Romina H Aspera-Werz; Tao Chen; Andreas K Nussler
Journal:  Int J Mol Sci       Date:  2018-08-03       Impact factor: 5.923
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.